Multimodality approaches to screening for lung cancer

Clinical Oncology - Robert Rintoul and Nitzan Rosenfeld

Despite modest improvements in 1- and 5-year survival lung cancer remains the most common cause of cancer death in the UK [1]. Unfortunately, around 70% of lung cancers are diagnosed at stage III or IV where the options for treatment with curative intent are greatly reduced [1]. Although targeted therapies and immunomodulators are improving life expectancy in advanced disease they have efficacy in only a small proportion of cases and long-term survival remains low....

21 Aug 2019